VolitionRx Limited (NYSE American: VNRX) has entered into a collaboration with Sysmex (TYO: 6869) to optimize Volition's Nu.Q® NETs H3.1 assay on the Sysmex diagnostic platform. The agreement supports Volition's strategy of licensing its proprietary Nu.Q® NETs technology to established global diagnostics companies that can leverage their disease expertise, regulatory capabilities and installed analyzer base to accelerate development and commercialization.
The collaboration has progressed beyond assay transfer and into the optimization phase for diseases associated with NETosis, a process implicated in conditions including sepsis and other acute and chronic diseases. Volition believes the Nu.Q® NETs assay could provide improved diagnostic information, support patient monitoring and address a commercial opportunity with an estimated total addressable market of $3.8 billion.
Volition is a multi-national company focused on advancing the science of epigenetics. The company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis.
The collaboration with Sysmex marks a significant step in bringing the Nu.Q® NETs assay to market. By partnering with a global diagnostics leader, Volition aims to accelerate the development and commercialization of the assay, potentially providing clinicians with a valuable tool for diagnosing and monitoring sepsis and other NETosis-related diseases. Sepsis is a life-threatening condition that arises when the body's response to infection causes widespread inflammation, leading to organ failure and death if not treated promptly. Improved diagnostic tools could enable earlier intervention and better patient outcomes.
The total addressable market for the Nu.Q® NETs assay is estimated at $3.8 billion, highlighting the significant commercial potential. For Volition, this collaboration aligns with its strategy of licensing its technology to established players rather than building its own sales and marketing infrastructure. For Sysmex, adding the Nu.Q® NETs assay to its platform could expand its diagnostic offerings in the area of infectious diseases and critical care.
For more information, visit the company's website at https://volition.com/. To view the full press release, visit https://ibn.fm/TSMG4.
